Case information
Conduct a refined search of the Supreme Court of Canada database to obtain details on the status of a matter before the Court.
35562
Apotex Inc., et al. v. Sanofi-Aventis, et al.
(Federal) (Civil) (By Leave)
(Sealing order)
Docket
Judgments on applications for leave to appeal are rendered by the Court, but are not necessarily unanimous.
| Date | Proceeding | Filed By (if applicable) |
|---|---|---|
| 2014-11-03 | Appeal closed | |
| 2014-11-03 | Discontinuance of the appeal | Apotex Inc. |
| 2014-10-31 | Correspondence received from, (Letter Form), Tamir Israel re: order of oral arguments | Centre for Intellectual Property Policy |
| 2014-10-31 | Correspondence received from, Jeffrey Beedell re: filing of the decision in the Celebrex patent will be filed with the respondent's condensed book | Sanofi-Aventis |
| 2014-10-30 | Correspondence received from, (Letter Form), Marc Richard re: order of counsel for oral submission | Sanofi-Aventis |
| 2014-10-29 | Correspondence received from, (Letter Form), Kang Lee re: submission will be in English and French | Fédération internationale des conseils en propriété intellectuelle |
| 2014-10-23 | Notice of appearance, (Letter Form), Jeremy de Beer and E. Richard Gold will be appearing | Centre for Intellectual Property Policy |
| 2014-10-23 | Notice of appearance, (Letter Form), Steven B. Garland and Colin B. Ingram will be appearing | International Association for the Protection of Intellectual Property ("AIPPI") |
| 2014-10-22 | Notice of appearance, (Letter Form), Patrick E. Kierans and Kristin Wall will be appearing | Canada's Research-Based Pharmaceutical Companies |
| 2014-10-21 | Notice of appearance, (Letter Form), David Aitken and Jonathan Stainsby will be appearing | Canadian Generic Pharmaceutical Association |
| 2014-10-21 |
Order by, Wa, FURTHER TO THE ORDER dated July 22, 2014, granting leave to intervene to the Fédération internationale des conseils en propriété intellectuelle, Canada’s Research-Based Pharmaceutical Companies, the Centre for Intellectual Property Policy, the International Association for the Protection of Intellectual Property, BIOTECanada and the Canadian Generic Pharmaceutical Association; IT IS HEREBY FURTHER ORDERED THAT the said six (6) interveners are each granted permission to present oral argument not exceeding 10 minutes at the hearing of the appeal. Granted |
|
| 2014-10-20 | Correspondence received from, (Letter Form), Request 2 reserved seats | BIOTECanada |
| 2014-10-20 | Notice of appearance, (Letter Form), Jamie Mills and Chantal Sanders will be appearing and Mr. Mills will make oral presentation | BIOTECanada |
| 2014-10-20 | Notice of appearance, (Letter Form), Julie Desrosiers and Kang Lee will be appearing and Me Desrosiers will present oral argument | Fédération internationale des conseils en propriété intellectuelle |
| 2014-10-20 | Notice of appearance, (Letter Form), H.B. Radomski, Richard Naiberg, Nando DeLuca and Sandon Shogilev will be appearing | Apotex Inc. |
| 2014-10-15 | Correspondence received from, 3 reserved seats requested | International Association for the Protection of Intellectual Property ("AIPPI") |
| 2014-10-10 | Other book of authorities, (Book Form), Completed on: 2014-10-10 | Sanofi-Aventis |
| 2014-10-10 | Supplemental document, Sur-reply, service and e-filing form missing, Incomplete | Sanofi-Aventis |
| 2014-10-10 | Correspondence received from, Fédération internationale des conseils en propriété intellectuelle - 4 reserved seats requested | Fédération internationale des conseils en propriété intellectuelle |
| 2014-10-07 | Correspondence received from, Canada's Research-Based Pharmaceutical Companies- Two reserved seats requested | Canada's Research-Based Pharmaceutical Companies |
| 2014-10-02 | Order on motion to strike out, (by Justice ROTHSTEIN) | |
| 2014-10-02 |
Decision on motion to strike out, Ro, UPON APPLICATION by the respondents for an order striking the reply factum of the appellants in its entirety or alternatively, granting leave to file a reply factum of up to 5 pages. AND THE MATERIAL FILED having been read; IT IS HEREBY ORDERED THAT: The application by the respondents to strike the reply factum of the appellants in its entirety is dismissed. The application by the respondents, in the alternative, to file a sur-reply factum of up to 5 pages is granted. The reply factum is to be served and filed on or before October 10, 2014. No order as to costs. Dismissed, no order as to costs |
|
| 2014-10-02 | Submission of motion to strike out, Ro | |
| 2014-10-01 | Appeal perfected for hearing | |
| 2014-09-30 | Appellant's book of authorities, (Book Form), for the reply factum, Completed on: 2014-09-30 | Apotex Inc. |
| 2014-09-30 | Reply factum on appeal, (Book Form), Appellants' Reply Factum, Completed on: 2014-09-30, (Electronic version filed on 2014-09-30) | Apotex Inc. |
| 2014-09-30 | Respondent's book of authorities, for the reply factum, Completed on: 2014-09-30, (Electronic version filed on 2014-09-30) | Sanofi-Aventis |
| 2014-09-30 | Reply factum on appeal, Completed on: 2014-09-30, (Electronic version filed on 2014-10-01) | Sanofi-Aventis |
| 2014-09-19 | Correspondence received from, 8 reserved seats requested | Apotex Inc. |
| 2014-09-17 | Correspondence received from, Anna Hucman, by email, Re: request for 2 reserved seats | Canadian Generic Pharmaceutical Association |
| 2014-09-16 | Intervener's book of authorities, Completed on: 2014-09-16, (Electronic version filed on 2014-09-16) | Centre for Intellectual Property Policy |
| 2014-09-16 | Intervener's factum, Completed on: 2014-09-16, (Electronic version filed on 2014-09-16) | Centre for Intellectual Property Policy |
| 2014-09-16 | Intervener's book of authorities, Completed on: 2014-09-16, (Electronic version filed on 2014-09-16) | Canada's Research-Based Pharmaceutical Companies |
| 2014-09-16 | Intervener's factum, Completed on: 2014-09-16, (Electronic version filed on 2014-09-16) | Canada's Research-Based Pharmaceutical Companies |
| 2014-09-16 | Intervener's book of authorities, Completed on: 2014-09-16, (Electronic version filed on 2014-09-16) | International Association for the Protection of Intellectual Property ("AIPPI") |
| 2014-09-16 | Intervener's factum, Completed on: 2014-09-16, (Electronic version filed on 2014-09-16) | International Association for the Protection of Intellectual Property ("AIPPI") |
| 2014-09-16 | Intervener's book of authorities, (2 volumes), Completed on: 2014-09-16 | Fédération internationale des conseils en propriété intellectuelle |
| 2014-09-16 | Intervener's factum, Completed on: 2014-09-16 | Fédération internationale des conseils en propriété intellectuelle |
| 2014-09-16 | Intervener's book of authorities, Completed on: 2014-09-16, (Electronic version filed on 2014-09-16) | BIOTECanada |
| 2014-09-16 | Intervener's factum, Completed on: 2014-09-16, (Electronic version filed on 2014-09-16) | BIOTECanada |
| 2014-09-16 | Intervener's book of authorities, Completed on: 2014-09-16 | Canadian Generic Pharmaceutical Association |
| 2014-09-16 | Intervener's factum, Completed on: 2014-09-16 | Canadian Generic Pharmaceutical Association |
| 2014-09-12 | Reply to motion to strike out, (Book Form), Original copy missing., Completed on: 2014-09-12, (Electronic version filed on 2014-09-12) | Sanofi-Aventis |
| 2014-09-08 | Notice of appearance, Marc Richard and Livia Aumand will be present for the hearing for the Respondents, and Anthony G. Creber will make oral arguments. | Sanofi-Aventis |
| 2014-09-08 | Correspondence received from, Counsel for the Respondents Sanofi and BMS requests 9 seats (amended request rec'd 2014-10-23 for 11 seats - re-amended rec'd 2014-10-31 for a total of 13 seats) | Sanofi-Aventis |
| 2014-09-08 | Notice of hearing sent to parties | |
| 2014-09-05 | Response to motion to strike out, (Book Form), Appellant's Reply Factum, Completed on: 2014-09-05, (Electronic version filed on 2014-09-09) | Apotex Inc. |
| 2014-09-05 | Appeal hearing scheduled, 2014-11-04, (previously tentatively scheduled for November 3, 2014) | |
| 2014-08-26 | Motion to strike out, (Book Form), Appellant's Reply Factum, Completed on: 2014-08-26, (Electronic version filed on 2014-08-26) | Sanofi-Aventis |
| 2014-08-12 | Order on motion to file a reply factum on appeal, (by ROTHSTEIN J.) | |
| 2014-08-12 |
Decision on the motion to file a reply factum on appeal, Ro, UPON APPLICATION by the respondents for an order granting leave to serve and file a single factum not exceeding 10 pages in reply to the interveners, together with any supplemental book of authorities, on or before September 30, 2014; AND THE MATERIAL HAVING BEEN FILED; IT IS HEREBY ORDERED THAT: The motion is granted. Granted |
|
| 2014-08-12 | Submission of motion to file a reply factum on appeal, Ro | |
| 2014-08-06 | Other book of authorities, (2 volumes), Completed on: 2014-08-06 | Apotex Inc. |
| 2014-08-06 | Reply factum on appeal, Pursuant to Rule 29(4), Completed on: 2014-08-06 | Apotex Inc. |
| 2014-07-24 | Certificate of counsel (attesting to record) | Sanofi-Aventis |
| 2014-07-24 | Motion to file a reply factum on appeal, (Letter Form), Completed on: 2014-07-31, (Printed version filed on 2014-07-24) | Sanofi-Aventis |
| 2014-07-22 | Order on motion for leave to intervene, (by ABELLA J.) | |
| 2014-07-22 |
Decision on the motion for leave to intervene, Abe, UPON APPLICATIONS by the Fédération internationale des conseils en propriété intellectuelle, Canada’s Research-Based Pharmaceutical Companies, the Centre for Intellectual Property Policy, the International Association for the Protection of Intellectual Property, BIOTECanada and the Canadian Generic Pharmaceutical Association for leave to intervene in the above appeal; AND THE MATERIAL FILED having been read; IT IS HEREBY ORDERED THAT: The motions for leave to intervene of the Fédération internationale des conseils en propriété intellectuelle, Canada’s Research-Based Pharmaceutical Companies, the Centre for Intellectual Property Policy, the International Association for the Protection of Intellectual Property, BIOTECanada and the Canadian Generic Pharmaceutical Association are granted and the said interveners shall be entitled to each serve and file a factum not to exceed 10 pages in length on or before September 16, 2014. The requests to present oral argument are deferred to a date following receipt and consideration of the written arguments of the parties and the interveners. The interveners are not entitled to raise new issues or to adduce further evidence or otherwise to supplement the record of the parties. Pursuant to Rule 59(1)(a) of the Rules of the Supreme Court of Canada, the interveners shall pay to the appellants and respondents any additional disbursements occasioned to the appellants and respondents by their interventions. The appellants are permitted to serve and file a single factum not exceeding 10 pages in reply to the interveners on or before September 30, 2014. Granted |
|
| 2014-07-22 | Submission of motion for leave to intervene, Abe | |
| 2014-07-21 | Correspondence received from, Jeff Beedell re: Confidentiality Order | Sanofi-Aventis |
| 2014-07-21 | Supplemental document, Authorities, Completed on: 2014-07-21 | Sanofi-Aventis |
| 2014-07-21 | Respondent's book of authorities, (Book Form), Completed on: 2014-07-21 | Sanofi-Aventis |
| 2014-07-21 | Respondent's record, (Book Form), 10 Volumes (Volumes 1, 5, 6 and 10 are sealed), Completed on: 2014-07-21 | Sanofi-Aventis |
| 2014-07-21 | Respondent's factum, (Book Form), Completed on: 2014-07-21 | Sanofi-Aventis |
| 2014-07-10 | Reply to the motion for leave to intervene, (Letter Form), Completed on: 2014-07-10, (Electronic version filed on 2014-07-10) | Fédération internationale des conseils en propriété intellectuelle |
| 2014-07-10 | Reply to the motion for leave to intervene, (Book Form), Completed on: 2014-07-10, (Electronic version filed on 2014-07-11) | Canada's Research-Based Pharmaceutical Companies |
| 2014-07-10 | Reply to the motion for leave to intervene, (Letter Form), Completed on: 2014-07-10, (Printed version filed on 2014-07-10) | Centre for Intellectual Property Policy |
| 2014-07-10 | Reply to the motion for leave to intervene, Reply to the appellants response, Completed on: 2014-07-10 | Canadian Generic Pharmaceutical Association |
| 2014-07-10 | Reply to the motion for leave to intervene, Reply to the respondents response, Completed on: 2014-07-10 | Canadian Generic Pharmaceutical Association |
| 2014-07-10 | Reply to the motion for leave to intervene, Completed on: 2014-07-10 | International Association for the Protection of Intellectual Property ("AIPPI") |
| 2014-07-10 | Reply to the motion for leave to intervene, Completed on: 2014-07-10 | BIOTECanada |
| 2014-07-03 | Response to the motion for leave to intervene, (Letter Form), Response to CGPA., Completed on: 2014-07-03, (Electronic version filed on 2014-07-03) | Apotex Inc. |
| 2014-07-03 | Response to the motion for leave to intervene, (Letter Form), Response to CRBPC, Biotec and CGPA, Completed on: 2014-07-03 | Sanofi-Aventis |
| 2014-07-03 | Response to the motion for leave to intervene, (Letter Form), Response to FICPI, AIPPI and CIPP, Completed on: 2014-07-03 | Sanofi-Aventis |
| 2014-07-03 | Response to the motion for leave to intervene, (Letter Form), Response to CIPP, Completed on: 2014-07-03 | Apotex Inc. |
| 2014-07-03 | Response to the motion for leave to intervene, (Book Form), Response to CRBPC, Completed on: 2014-07-03 | Apotex Inc. |
| 2014-07-03 | Response to the motion for leave to intervene, (Book Form), Response to AIPPI , Completed on: 2014-07-03 | Apotex Inc. |
| 2014-07-03 | Response to the motion for leave to intervene, (Book Form), Response to BIOTEC (2 volumes), Completed on: 2014-07-03 | Apotex Inc. |
| 2014-07-03 | Response to the motion for leave to intervene, (Book Form), Response to FICPI (2 volumes), Completed on: 2014-07-03 | Apotex Inc. |
| 2014-06-23 | Intervener's book of authorities, (Book Form), Completed on: 2014-06-23 | Canadian Generic Pharmaceutical Association |
| 2014-06-23 | Motion for leave to intervene, Completed on: 2014-06-24, (Electronic version filed on 2014-06-24) | Canadian Generic Pharmaceutical Association |
| 2014-06-23 | Motion for leave to intervene, (Book Form), Completed on: 2014-06-23, (Electronic version filed on 2014-06-23) | BIOTECanada |
| 2014-06-23 | Intervener's book of authorities, (Book Form), for the motion to intervene., Completed on: 2014-06-23, (Electronic version filed on 2014-06-23) | International Association for the Protection of Intellectual Property ("AIPPI") |
| 2014-06-23 | Motion for leave to intervene, (Book Form), Completed on: 2014-06-23, (Electronic version filed on 2014-06-23) | International Association for the Protection of Intellectual Property ("AIPPI") |
| 2014-06-23 | Motion for leave to intervene, (Book Form), Completed on: 2014-06-23, (Electronic version filed on 2014-06-23) | Centre for Intellectual Property Policy |
| 2014-06-23 | Certificate (on limitations to public access) | Canada's Research-Based Pharmaceutical Companies |
| 2014-06-23 | Notice of name | Canada's Research-Based Pharmaceutical Companies |
| 2014-06-23 | Motion for leave to intervene, (4 volumes), Completed on: 2014-06-23, (Electronic version filed on 2014-06-26) | Canada's Research-Based Pharmaceutical Companies |
| 2014-06-23 | Motion for leave to intervene, (Book Form), (3 volumes) , Completed on: 2014-06-23, (Electronic version filed on 2014-06-26) | Fédération internationale des conseils en propriété intellectuelle |
| 2014-05-28 | Certificate of counsel (attesting to record) | Apotex Inc. |
| 2014-05-26 | Certificate (on limitations to public access) | Apotex Inc. |
| 2014-05-26 | Appellant's book of authorities, (2 volumes), Completed on: 2014-05-26 | Apotex Inc. |
| 2014-05-26 | Appellant's record, Volumes I, X! and XIV are not sealed(16 volumes + XA, XB, XC AND XIA), Completed on: 2014-05-27 | Apotex Inc. |
| 2014-05-26 | Appellant's factum, Completed on: 2014-05-26 | Apotex Inc. |
| 2014-03-03 | Notice of appeal, (Letter Form), Completed on: 2014-03-03, (Electronic version filed on 2014-03-03) | Apotex Inc. |
| 2014-01-31 | Letter advising the parties of tentative hearing date and filing deadlines (Leave granted) | |
| 2014-01-31 | Copy of formal judgment sent to Registrar of the Court of Appeal and all parties | |
| 2014-01-31 | Judgment on leave sent to the parties | |
| 2014-01-30 |
Judgment of the Court on the application for leave to appeal, The motion for an extension of time to serve and file the application for leave to appeal is granted. The application for leave to appeal from the judgment of the Federal Court of Appeal, Number A-7-12, 2013 FCA 186, dated July 24, 2013, is granted with costs in the cause. Granted, with costs in the cause |
|
| 2014-01-30 |
Decision on motion to extend time to file and /or serve the leave application, see judgment Granted |
|
| 2013-12-16 | Submission of motion to extend time to file and/ or serve the leave application, Abe Ro Mo | |
| 2013-12-16 | All materials on application for leave submitted to the Judges, Abe Ro Mo | |
| 2013-11-12 | Applicant's reply to respondent's argument, (Book Form), Completed on: 2013-11-12 | Apotex Inc. |
| 2013-10-30 | Book of authorities, (Book Form) | Sanofi-Aventis |
| 2013-10-30 | Respondent's response on the application for leave to appeal, (Book Form), Completed on: 2013-10-30 | Sanofi-Aventis |
| 2013-10-08 | Motion to extend the time to file and or serve the application for leave to appeal, (Book Form), Completed on: 2013-10-08 | Apotex Inc. |
| 2013-10-01 | Letter acknowledging receipt of a complete application for leave to appeal | |
| 2013-10-01 | Application for leave to appeal, (Book Form), Vol. 1 to 5 (CD filed) (Extension of time rec'd), Completed on: 2013-10-10 | Apotex Inc. |
Parties
Please note that in the case of closed files, the “Status” column reflects the status of the parties at the time of the proceedings. For more information about the proceedings and about the dates when the file was open, please consult the docket of the case in question.
Main parties
| Name | Role | Status |
|---|---|---|
| Apotex Inc. | Appellant | Active |
| Apotex Pharmachem Inc. | Appellant | Active |
v.
| Name | Role | Status |
|---|---|---|
| Sanofi-Aventis | Respondent | Active |
| Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership | Respondent | Active |
Other parties
| Name | Role | Status |
|---|---|---|
| Fédération internationale des conseils en propriété intellectuelle | Intervener | Active |
| Canada's Research-Based Pharmaceutical Companies | Intervener | Active |
| Centre for Intellectual Property Policy | Intervener | Active |
| International Association for the Protection of Intellectual Property ("AIPPI") | Intervener | Active |
| BIOTECanada | Intervener | Active |
| Canadian Generic Pharmaceutical Association | Intervener | Active |
Counsel
Party: Apotex Inc.
Counsel
Harry B. Radomski
Nando De Luca
Richard Naiberg
Nando De Luca
Richard Naiberg
Goodmans LLP
3400 - 333 Bay Street
Toronto, Ontario
M5H 2S7
Telephone: (416) 979-2211
FAX: (416) 979-1234
Email: hradomski@goodmans.ca
3400 - 333 Bay Street
Toronto, Ontario
M5H 2S7
Telephone: (416) 979-2211
FAX: (416) 979-1234
Email: hradomski@goodmans.ca
Agent
Dougald E. Brown
Nelligan O'Brien Payne LLP
1500 - 50 O'Connor St.
Ottawa, Ontario
K1P 6L2
Telephone: (613) 231-8210
FAX: (613) 788-3661
Email: dougald.brown@nelligan.ca
1500 - 50 O'Connor St.
Ottawa, Ontario
K1P 6L2
Telephone: (613) 231-8210
FAX: (613) 788-3661
Email: dougald.brown@nelligan.ca
Party: Apotex Pharmachem Inc.
Counsel
Harry B. Radomski
Nando De Luca
Nando De Luca
Goodmans LLP
3400 - 333 Bay Street
Toronto, Ontario
M5H 2S7
Telephone: (416) 979-2211
FAX: (416) 979-1234
Email: hradomski@goodmans.ca
3400 - 333 Bay Street
Toronto, Ontario
M5H 2S7
Telephone: (416) 979-2211
FAX: (416) 979-1234
Email: hradomski@goodmans.ca
Agent
Dougald E. Brown
Nelligan O'Brien Payne LLP
1500 - 50 O'Connor St.
Ottawa, Ontario
K1P 6L2
Telephone: (613) 231-8210
FAX: (613) 788-3661
Email: dougald.brown@nelligan.ca
1500 - 50 O'Connor St.
Ottawa, Ontario
K1P 6L2
Telephone: (613) 231-8210
FAX: (613) 788-3661
Email: dougald.brown@nelligan.ca
Party: Sanofi-Aventis
Counsel
Anthony G. Creber
C. Wagner
Marc Richard
Livia Aumand
C. Wagner
Marc Richard
Livia Aumand
Gowling WLG (Canada) LLP
Suite 2600, Box 466
160 Elgin Street - Stn. D.
Ottawa, Ontario
K1P 1C3
Telephone: (613) 232-1781
FAX: (613) 563-9869
Email: Anthony.creber@gowlingwlg.com
Suite 2600, Box 466
160 Elgin Street - Stn. D.
Ottawa, Ontario
K1P 1C3
Telephone: (613) 232-1781
FAX: (613) 563-9869
Email: Anthony.creber@gowlingwlg.com
Party: Bristol-Myers Squibb Sanofi Pharmaceuticals Holding Partnership
Counsel
Anthony G. Creber
C. Wagner
Marc Richard
Livia Aumand
C. Wagner
Marc Richard
Livia Aumand
Gowling WLG (Canada) LLP
Suite 2600, Box 466
160 Elgin Street - Stn. D.
Ottawa, Ontario
K1P 1C3
Telephone: (613) 232-1781
FAX: (613) 563-9869
Email: Anthony.creber@gowlingwlg.com
Suite 2600, Box 466
160 Elgin Street - Stn. D.
Ottawa, Ontario
K1P 1C3
Telephone: (613) 232-1781
FAX: (613) 563-9869
Email: Anthony.creber@gowlingwlg.com
Party: Fédération internationale des conseils en propriété intellectuelle
Counsel
Julie Desrosiers
Kang Lee
J. AIdan O'Neil
Alain Leclerc
Kang Lee
J. AIdan O'Neil
Alain Leclerc
Fasken Martineau DuMoulin LLP
The Stock Exchange Tower, Suite 3400, Victoria Square
C.P. 242, Succ. Tour D/L Bourse
Montréal, Quebec
H4Z 1E9
Telephone: (514) 397-7400
FAX: (514) 397-7600
Email: jdesrosiers@mtl.fasken.com
The Stock Exchange Tower, Suite 3400, Victoria Square
C.P. 242, Succ. Tour D/L Bourse
Montréal, Quebec
H4Z 1E9
Telephone: (514) 397-7400
FAX: (514) 397-7600
Email: jdesrosiers@mtl.fasken.com
Agent
Gerald L. (Jay) Kerr-Wilson
Fasken Martineau DuMoulin LLP
1300 - 55 Metcalfe St.
Ottawa, Ontario
K1P 6L5
Telephone: (613) 236-3882
FAX: (613) 230-6423
Email: jkerrwilson@fasken.com
1300 - 55 Metcalfe St.
Ottawa, Ontario
K1P 6L5
Telephone: (613) 236-3882
FAX: (613) 230-6423
Email: jkerrwilson@fasken.com
Party: Canada's Research-Based Pharmaceutical Companies
Counsel
Patrick E. Kierans
Kristin Wall
Kristin Wall
Norton Rose Fulbright Canada LLP
Royal Bank Plaza, South Tower
Suite 3800, 200 Bay St., PO Box 84
Toronto, Ontario
M5J 2Z4
Telephone: (416) 216-3904
FAX: (416) 216-3930
Email: patrick.kierans@nortonrose.com
Royal Bank Plaza, South Tower
Suite 3800, 200 Bay St., PO Box 84
Toronto, Ontario
M5J 2Z4
Telephone: (416) 216-3904
FAX: (416) 216-3930
Email: patrick.kierans@nortonrose.com
Agent
Sally Gomery
Norton Rose Fulbright Canada LLP
1500-45 O'Connor Street
Ottawa, Ontario
K1P 1A4
Telephone: (613) 780-8604
FAX: (613) 230-5459
Email: sally.gomery@nortonrosefulbright.com
1500-45 O'Connor Street
Ottawa, Ontario
K1P 1A4
Telephone: (613) 780-8604
FAX: (613) 230-5459
Email: sally.gomery@nortonrosefulbright.com
Party: Centre for Intellectual Property Policy
Counsel
Jeremy de Beer
Jeremy de Beer Professional Corporation
676 Roosevelt Avenue
Ottawa, Ontario
K2A 2A7
Telephone: (613) 263-9155
FAX: (613) 562-5417
Email: Jeremy@JeremydeBeer.ca
676 Roosevelt Avenue
Ottawa, Ontario
K2A 2A7
Telephone: (613) 263-9155
FAX: (613) 562-5417
Email: Jeremy@JeremydeBeer.ca
Agent
Tamir Israel
Samuelson-Glushko Canadian Internet Policy & Public Interest Clinic
University of Ottawa, Faculty of Law
57 Louis Pasteur Street, Ontario
K1N 6N5
Telephone: (613) 562-5800 Ext: 2914
FAX: (613) 562-5417
Email: tisrael@cippic.ca
University of Ottawa, Faculty of Law
57 Louis Pasteur Street, Ontario
K1N 6N5
Telephone: (613) 562-5800 Ext: 2914
FAX: (613) 562-5417
Email: tisrael@cippic.ca
Party: International Association for the Protection of Intellectual Property ("AIPPI")
Counsel
Steven B. Garland
Colin B. Ingram
Colin B. Ingram
Smart & Biggar
900 - 55 Metcalfe Street
P.O. Box 2999, Station D
Ottawa, Ontario
K1P 5Y6
Telephone: (613) 232-2486
FAX: (613) 232-8440
Email: sgarland@smart-biggar.ca
900 - 55 Metcalfe Street
P.O. Box 2999, Station D
Ottawa, Ontario
K1P 5Y6
Telephone: (613) 232-2486
FAX: (613) 232-8440
Email: sgarland@smart-biggar.ca
Party: BIOTECanada
Counsel
James Eliot Mills
Borden Ladner Gervais LLP
World Exchange Plaza
1100-100 Queen Street
Ottawa, Ontario
K1P 1J9
Telephone: (613) 369-4782
FAX: (613) 230-8842
World Exchange Plaza
1100-100 Queen Street
Ottawa, Ontario
K1P 1J9
Telephone: (613) 369-4782
FAX: (613) 230-8842
Agent
Nadia Effendi
Borden Ladner Gervais LLP
World Exchange Plaza
100 Queen Street, suite 1300
Ottawa, Ontario
K1P 1J9
Telephone: (613) 787-3562
FAX: (613) 230-8842
Email: neffendi@blg.com
World Exchange Plaza
100 Queen Street, suite 1300
Ottawa, Ontario
K1P 1J9
Telephone: (613) 787-3562
FAX: (613) 230-8842
Email: neffendi@blg.com
Party: Canadian Generic Pharmaceutical Association
Counsel
David W. Aitken
Jonathan Stainsby
Jonathan Stainsby
Aitken Klee LLP
100 Queen Street
Suite 300
Ottawa, Ontario
K1P 1J9
Telephone: (613) 903-5099
FAX: (613) 695-5854
Email: daitken@aitkenklee.com
100 Queen Street
Suite 300
Ottawa, Ontario
K1P 1J9
Telephone: (613) 903-5099
FAX: (613) 695-5854
Email: daitken@aitkenklee.com
Summary
Keywords
None.
Summary
Case summaries are prepared by the Office of the Registrar of the Supreme Court of Canada (Law Branch). Please note that summaries are not provided to the Judges of the Court. They are placed on the Court file and website for information purposes only.
Intellectual property – Patents – Medicines – Patent for medicine held to be valid and infringed by generic manufacturer – How the utility promised by a patent is to be identified and ascertained – How an appellate court is to review factual findings of trial judge as to how skilled addressee would understand the promised utility – How limitations periods are to be applied in respect of activity that only involves conduct, including import and export, in one province.
Plavix is a drug useful in inhibiting platelet aggregation activity in the blood which was developed, patented, and marketed by the respondents (collectively, “Sanofi”). The ‘777 Patent for Plavix is considered to be a selection patent that claims a subset of compounds which are already within the scope of the prior genus ‘875 Patent. The active ingredient in Plavix is clopidogrel bisulphate, the dextro-rotatory isomer of the racemate, having beneficial properties over both the racemate and the levo-rotatory isomer. Apotex Inc. (“Apotex”) attempted to market its own version of clopidogrel bisulfate. It applied for a Notice of Compliance from the Minister of Health, alleging that its version of clopidogrel did not infringe Sanofi’s patent. Apotex also alleged that the ‘777 Patent for Plavix was invalid on several grounds. Sanofi successfully obtained an order prohibiting the Minister from issuing the Notice of Compliance to Apotex. This order was upheld on appeal and again at the Supreme Court of Canada. Apotex then commenced an impeachment action in the Federal Court seeking a declaration that the ‘777 Patent was invalid on several grounds including lack of utility. Sanofi commenced its own action, alleging that Apotex had infringed its patent by importing clopidogrel into Canada and then exporting it from Canada for sale in other countries including the United States. The two actions were consolidated.
Lower court rulings
December 12, 2011
Federal Court
2011 FC 1486, T-644-09. T-933-09
Federal Court
2011 FC 1486, T-644-09. T-933-09
Apotex’s impeachment action of ‘777 Patent based on lack of utility and obviousness allowed; Sanofi’s infringement action dismissed
July 24, 2013
Federal Court of Appeal
2013 FCA 186, A-7-12
Federal Court of Appeal
2013 FCA 186, A-7-12
Sanofi’s appeal allowed; Sanofi’s action for infringement allowed; Apotex’s impeachment action dismissed
Memorandums of argument on application for leave to appeal
The memorandums of argument on an application for leave to appeal will be posted here 30 days after leave to appeal has been granted unless they contain personal information, information that is subject to a publication ban, or any other information that is not part of the public record. You may also obtain copies of the memorandum by filing out the Request for Court records form or by contacting the Court’s Records Centre either by email at records-dossiers@scc-csc.ca or by telephone at 613‑996‑7933 or at 1‑888‑551‑1185.
If you have questions about a memorandum of argument or want to use a memorandum of argument, please contact the author of the memorandum of argument directly. Their name appears at the end of the memorandum of argument. The contact information for counsel is found in the “Counsel” tab of this page.
Downloadable PDFs
Not available
Related links
Factums on appeal
The factums of the appellant, the respondent and the intervener will be posted here at least 2 weeks before the hearing unless they contain personal information, information that is subject to a publication ban, or any other information that is not part of the public record. You may also obtain copies of factums by filling out the Request for Court records form or by contacting the Court’s Records Centre either by email at records-dossiers@scc-csc.ca or by telephone at 613‑996‑7933 or at 1‑888‑551‑1185.
If you have questions about a factum or want permission to use a factum, please contact the author of the factum directly. Their contact information appears on the first page of each factum.
Downloadable PDFs
Not available
Related links
Date modified: 2025-05-13